Johnson & Johnson Reports Third-Quarter EPS of 9 Cents
Johnson & Johnson reported third-quarter EPS of 9 cents, down from $2.12 a year earlier. Results included a one-time charge for a proposed talc litigation resolution, along with charges tied to its Firefly Bio acquisition and Sail Biomedicine collaboration.
12 a year earlier. Results were weighed down by a one-time charge for a proposed resolution to talc litigation. The company also recorded charges related to its acquisition of Firefly Bio and its collaboration with Sail Biomedicine.